Read twice and referred to the Committee on Finance.
This bill creates a new Radiation Oncology Case Rate Value Based Payment Program (ROCR Program) under Medicare. It pays per-episode bundled payments for defined radiation therapy episodes, sets national base rates tied to 2021 M-code base rates, requires accreditation and quality reporting, provides an add-on payment to address transportation insecurity, exempts ROCR savings from budget-neutrality adjustments, and adds a statutory exception permitting certain free or discounted patient transportation.
Progressives emphasize equity add-on and accreditation as quality gains.
Relative to its intended legislative type, this bill is a detailed substantive policy change that establishes a new, statutory Medicare value-based payment program for radiation oncology with many specific structural elements.
This bill creates a new Radiation Oncology Case Rate Value Based Payment Program (ROCR Program) under Medicare.
It pays per-episode bundled payments for defined radiation therapy episodes, sets national base rates tied to 2021 M-code base rates, requires accreditation and quality reporting, provides an add-on payment to address transportation insecurity, exempts ROCR savings from budget-neutrality adjustments, and adds a statutory exception permitting certain free or discounted patient transportation.
The bill also excludes participating ROCR providers from MIPS and tasks the GAO with multi-year evaluations.
Targeted Medicare payment change with technical design and stakeholder protections improves prospects, but complexity, potential provider opposition, and budgetary concerns lower likelihood.
Relative to its intended legislative type, this bill is a detailed substantive policy change that establishes a new, statutory Medicare value-based payment program for radiation oncology with many specific structural elements. It integrates directly with existing Medicare law, prescribes definitions, payment timing, update cycles, accreditation requirements, and postimplementation GAO review. The bill leaves a number of important operational and fiscal details to administrative rulemaking and does not provide fiscal estimations or appropriations.
Progressives emphasize equity add-on and accreditation as quality gains.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize equity add-on and accreditation as quality gains.
Generally supportive of value-based approaches that improve access and equity, while cautious about patient cost-sharing and exclusions.
Views the transportation add-on and accreditation requirements as promising for equity and quality, but would want stronger protections against increased out-of-pocket costs and slower inclusion of new technologies.
Views the bill as a pragmatic move toward episode-based, value-oriented payments that stabilize rates and encourage efficiency.
Supports monitoring and phased implementation, but is concerned about transitional access risks, the long new-technology delay, and fiscal implications of exempting savings from budget-neutrality adjustments.
Skeptical of increased federal regulation and new payment mandates.
Concerns focus on federal rulemaking, accreditation mandates, potential reduced provider revenues, and long-term spending effects from add-ons and budget-neutrality exemptions.
Prefers state flexibility and market-based solutions.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Targeted Medicare payment change with technical design and stakeholder protections improves prospects, but complexity, potential provider opposition, and budgetary concerns lower likelihood.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize equity add-on and accreditation as quality gains.
Targeted Medicare payment change with technical design and stakeholder protections improves prospects, but complexity, potential provider o…
Relative to its intended legislative type, this bill is a detailed substantive policy change that establishes a new, statutory Medicare value-based payment program for radiation oncology with many specific structural el…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.